Engineered MSCs from Patient-Specific iPS Cells

  • Irina Eberle
  • Mohsen Moslem
  • Reinhard Henschler
  • Tobias Cantz
Chapter
Part of the Advances in Biochemical Engineering/Biotechnology book series (ABE, volume 130)

Abstract

Mesenchymal stroma/stem cells (MSCs) represent a heterogenic cell population that can be isolated from various tissues of the body or can be generated from pluripotent stem cells by in vitro differentiation. Various promising pre-clinical and clinical studies suggest that MSCs might stimulate endogenous regeneration and/or act as anti-inflammatory agents, which could be of high therapeutic relevance for a number of diseases, including graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, inflammatory bowel diseases, or some forms of liver failure. Notably, conflicting results of various studies illustrated that the source of MSCs, the cultivation condition, and the way of administration have important effects on the desired clinical effect. Some of the involved molecular pathways have recently been elucidated and an artificial modulation of these pathways by engineered MSCs might result in superfunctional MSCs for enhanced endogenous regeneration or anti-inflammatory response. In this review, we summarize important findings of conventional MSCs for applications in gastroenterology and we describe the state-of-the-art for the generation of patient-derived iPS cells that eventually might provide genetically engineered superfunctional iPS cells for advanced cell therapies.

Graphical Abstract

Keywords

Cell transplantation Induced pluripotent stem cells (iPSC) Inflammatory bowel diseases Liver diseases Mesenchymal stromal (stem) cells (MSC) 

References

  1. 1.
    Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilic J, Pekarik V, Tiscornia G, Edel M, Boue S, Izpisua Belmonte JC (2008) Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26(11):1276–1284Google Scholar
  2. 2.
    Allison M (2009) Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27(11):966–967Google Scholar
  3. 3.
    Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R et al (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84(4):1320–1327Google Scholar
  4. 4.
    Augello A, Kurth TB, De Bari C (2010) Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cell Mater 20:121–133Google Scholar
  5. 5.
    Aurich H, Sgodda M, Kaltwasser P, Vetter M, Weise A, Liehr T, Brulport M, Hengstler JG, Dollinger MM, Fleig WE, Christ B (2009) Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58(4):570–581Google Scholar
  6. 6.
    Aurich I, Mueller LP, Aurich H, Luetzkendorf J, Tisljar K, Dollinger MM, Schormann W, Walldorf J, Hengstler JG, Fleig WE, Christ B (2007) Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 56(3):405–415Google Scholar
  7. 7.
    Barberi T, Willis LM, Socci ND, Studer L (2005) Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2(6):e161Google Scholar
  8. 8.
    Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1):42–48Google Scholar
  9. 9.
    Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, Kupriyanov S, Baldwin KK (2009) Adult mice generated from induced pluripotent stem cells. Nature 461(7260):91–94Google Scholar
  10. 10.
    Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3(7):521–533Google Scholar
  11. 11.
    Cantz T, Martin U (2010) Induced pluripotent stem cells: characteristics and perspectives. Adv Biochem Eng Biotechnol 123:107–126Google Scholar
  12. 12.
    Cantz T, Sharma AD, Jochheim-Richter A, Arseniev L, Klein C, Manns MP, Ott M (2004) Reevaluation of bone marrow-derived cells as a source for hepatocyte regeneration. Cell Transp 13(6):659–666Google Scholar
  13. 13.
    Carey BW, Markoulaki S, Hanna JH, Faddah DA, Buganim Y, Kim J, Ganz K, Steine EJ, Cassady JP, Creyghton MP, Welstead GG, Gao Q, Jaenisch R (2011) Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 9(6):588–598Google Scholar
  14. 14.
    Carmona G, Gottig S, Orlandi A, Scheele J, Bauerle T, Jugold M, Kiessling F, Henschler R, Zeiher AM, Dimmeler S, Chavakis E (2009) Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis. Blood 113(2):488–497Google Scholar
  15. 15.
    Chamberlain G, Fox J, Ashton B, Middleton J (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25(11):2739–2749Google Scholar
  16. 16.
    Chen YS, Pelekanos RA, Ellis RL, Horne R, Wolvetang EJ, Fisk NM (2012) Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Trans Med 1:83–95Google Scholar
  17. 17.
    Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60(6):788–798Google Scholar
  18. 18.
    Cormier JT, zur Nieden NI, Rancourt DE, Kallos MS (2006) Expansion of undifferentiated murine embryonic stem cells as aggregates in suspension culture bioreactors. Tissue Eng 12 (11):3233–3245Google Scholar
  19. 19.
    de Peppo GM, Svensson S, Lenneras M, Synnergren J, Stenberg J, Strehl R, Hyllner J, Thomsen P, Karlsson C (2010) Human embryonic mesodermal progenitors highly resemble human mesenchymal stem cells and display high potential for tissue engineering applications. Tissue Eng Part A 16(7):2161–2182Google Scholar
  20. 20.
    Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE (2001) Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 98(7):2052–2058Google Scholar
  21. 21.
    Diederichs S, Roker S, Marten D, Peterbauer A, Scheper T, van Griensven M, Kasper C (2009) Dynamic cultivation of human mesenchymal stem cells in a rotating bed bioreactor system based on the Z RP platform. Biotechnol Prog 25(6):1762–1771Google Scholar
  22. 22.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317Google Scholar
  23. 23.
    Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, Kooy-Winkelaar EM, Koning F, Zwaginga JJ, Fidder HH, Verhaar AP, Fibbe WE, van den Brink GR, Hommes DW (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59(12):1662–1669Google Scholar
  24. 24.
    El-Ansary M, Abdel-Aziz I, Mogawer S, Abdel-Hamid S, Hammam O, Teaema S, Wahdan M (2011) Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev 8(3):972–981Google Scholar
  25. 25.
    Eminli S, Utikal J, Arnold K, Jaenisch R, Hochedlinger K (2008) Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 26(10):2467–2474Google Scholar
  26. 26.
    Engel MA, Neurath MF (2010) New pathophysiological insights and modern treatment of IBD. J Gastroenterol 45(6):571–583Google Scholar
  27. 27.
    Ferrara JL, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transpl 5(6):347–356Google Scholar
  28. 28.
    Fridley KM, Fernandez I, Li MT, Kettlewell RB, Roy K (2010) Unique differentiation profile of mouse embryonic stem cells in rotary and stirred tank bioreactors. Tissue Eng Part A 16(11):3285–3298Google Scholar
  29. 29.
    Friedman SL (2007) Reversibility of hepatic fibrosis and cirrhosis—is it all hype? Nat Clin Pract Gastroenterol Hepatol 4(5):236–237Google Scholar
  30. 30.
    Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M (2009) Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 85(8):348–362Google Scholar
  31. 31.
    Garcia-Bosch O, Ricart E, Panes J (2010) Review article: stem cell therapies for inflammatory bowel disease—efficacy and safety. Aliment Pharmacol Ther 32(8):939–952Google Scholar
  32. 32.
    Giuliani M, Oudrhiri N, Noman ZM, Vernochet A, Chouaib S, Azzarone B, Durrbach A, Bennaceur-Griscelli A (2011) Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 118(12):3254–3262Google Scholar
  33. 33.
    Gonzalez F, Boue S, Izpisua Belmonte JC (2011) Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 12(4):231–242Google Scholar
  34. 34.
    Gruenloh W, Kambal A, Sondergaard C, McGee J, Nacey C, Kalomoiris S, Pepper K, Olson S, Fierro F, Nolta JA (2011) Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. Tissue Eng Part A 17(11–12):1517–1525Google Scholar
  35. 35.
    Haase A, Olmer R, Schwanke K, Wunderlich S, Merkert S, Hess C, Zweigerdt R, Gruh I, Meyer J, Wagner S, Maier LS, Han DW, Glage S, Miller K, Fischer P, Scholer HR, Martin U (2009) Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 5(4):434–441Google Scholar
  36. 36.
    Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462(7273):595–601Google Scholar
  37. 37.
    Hung CN, Mar K, Chang HC, Chiang YL, Hu HY, Lai CC, Chu RM, Ma CM (2011) A comparison between adipose tissue and dental pulp as sources of MSCs for tooth regeneration. Biomaterials 32(29):6995–7005Google Scholar
  38. 38.
    Hwang NS, Varghese S, Lee HJ, Zhang Z, Ye Z, Bae J, Cheng L, Elisseeff J (2008) In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci U S A 105(52):20641–20646Google Scholar
  39. 39.
    in ‘t Anker PS, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE (2003) Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88(8):845–852Google Scholar
  40. 40.
    Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, Panetta NJ, Chen ZY, Robbins RC, Kay MA, Longaker MT, Wu JC (2010) A nonviral minicircle vector for deriving human iPS cells. Nat Methods 7(3):197–199Google Scholar
  41. 41.
    Judson RL, Babiarz JE, Venere M, Blelloch R (2009) Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 27(5):459–461Google Scholar
  42. 42.
    Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K (2009) Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239):771–775Google Scholar
  43. 43.
    Kasper G, Mao L, Geissler S, Draycheva A, Trippens J, Kuhnisch J, Tschirschmann M, Kaspar K, Perka C, Duda GN, Klose J (2009) Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 27(6):1288–1297Google Scholar
  44. 44.
    Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J (2009) Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl 15(7):804–811Google Scholar
  45. 45.
    Kemp K, Gray E, Mallam E, Scolding N, Wilkins A (2010) Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Rev 6(4):548–559Google Scholar
  46. 46.
    Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hunerliturkoglu A, Haas R (2001) Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transpl 28(1):47–49Google Scholar
  47. 47.
    Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M (2000) Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6(11):1229–1234Google Scholar
  48. 48.
    Laurila JP, Laatikainen L, Castellone MD, Trivedi P, Heikkila J, Hinkkanen A, Hematti P, Laukkanen MO (2009) Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. Cytotherapy 11(6):726–737Google Scholar
  49. 49.
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371(9624):1579–1586Google Scholar
  50. 50.
    Lian Q, Lye E, Suan Yeo K, Khia Way Tan E, Salto-Tellez M, Liu TM, Palanisamy N, El Oakley RM, Lee EH, Lim B, Lim SK (2007) Derivation of clinically compliant MSCs from CD105+, CD24− differentiated human ESCs. Stem Cells 25(2):425–436Google Scholar
  51. 51.
    Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Lam FF, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF (2010) Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 121(9):1113–1123Google Scholar
  52. 52.
    Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6(11):1282–1286Google Scholar
  53. 53.
    Liu CH, Hwang SM (2005) Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 32(6):270–279Google Scholar
  54. 54.
    Liu Y, Goldberg AJ, Dennis JE, Gronowicz GA, Kuhn LT (2012) One-step derivation of mesenchymal stem cell (MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. PLoS One 7(3):e33225Google Scholar
  55. 55.
    Locke M, Feisst V, Dunbar PR (2011) Concise review: human adipose-derived stem cells: separating promise from clinical need. Stem Cells 29(3):404–411Google Scholar
  56. 56.
    Mark AL, Sun Z, Warren DS, Lonze BE, Knabel MK, Melville Williams GM, Locke JE, Montgomery RA, Cameron AM (2010) Stem cell mobilization is life saving in an animal model of acute liver failure. Ann Surg 252(4):591–596Google Scholar
  57. 57.
    Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12):4619–4621Google Scholar
  58. 58.
    Mohamadnejad M, Namiri M, Bagheri M, Hashemi SM, Ghanaati H, Zare Mehrjardi N, Kazemi Ashtiani S, Malekzadeh R, Baharvand H (2007) Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 13(24):3359–3363Google Scholar
  59. 59.
    Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219(3):294–305Google Scholar
  60. 60.
    Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (2008) Generation of mouse induced pluripotent stem cells without viral vectors. Science 322(5903):949–953Google Scholar
  61. 61.
    Olivier EN, Rybicki AC, Bouhassira EE (2006) Differentiation of human embryonic stem cells into bipotent mesenchymal stem cells. Stem Cells 24(8):1914–1922Google Scholar
  62. 62.
    Olmer R, Lange A, Selzer S, Kasper C, Haverich A, Martin U, Zweigerdt R (2012) Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng Part C Methods. doi:10.1089/ten.tec.2011.0717 [Epub ahead of print]
  63. 63.
    Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M (2009) Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A 106(31):12759–12764Google Scholar
  64. 64.
    Penn MS, Ellis S, Gandhi S, Greenbaum A, Hodes Z, Mendelsohn FO, Strasser D, Ting AE, Sherman W (2012) Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res 110(2):304–311Google Scholar
  65. 65.
    Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP (1999) Bone marrow as a potential source of hepatic oval cells. Science 284(5417):1168–1170Google Scholar
  66. 66.
    Pfaff N, Fiedler J, Holzmann A, Schambach A, Moritz T, Cantz T, Thum T (2011) miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBO Rep 12(11):1153–1159Google Scholar
  67. 67.
    Pfaff N, Moritz T, Thum T, Cantz T (2012) miRNAs involved in the generation, maintenance, and differentiation of pluripotent stem cells. J Mol Med 90(7):747–752Google Scholar
  68. 68.
    Poynard T, Yuen MF, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet 362(9401):2095–2100Google Scholar
  69. 69.
    Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B, Aschan J, Barkholt L, Le Blanc K (2006) Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10):1390–1397Google Scholar
  70. 70.
    Saito F, Nakatani T, Iwase M, Maeda Y, Hirakawa A, Murao Y, Suzuki Y, Onodera R, Fukushima M, Ide C (2008) Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. J Trauma 64(1):53–59Google Scholar
  71. 71.
    Salas A, Ricart E, Panes J (2009) Cell therapies for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 3(4):321–324Google Scholar
  72. 72.
    Sanchez L, Gutierrez-Aranda I, Ligero G, Rubio R, Munoz-Lopez M, Garcia-Perez JL, Ramos V, Real PJ, Bueno C, Rodriguez R, Delgado M, Menendez P (2011) Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells 29(2):251–262Google Scholar
  73. 73.
    Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y (2005) Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 106(2):756–763Google Scholar
  74. 74.
    Sharma AD, Cantz T, Manns MP, Ott M (2006) The role of stem cells in physiology, pathophysiology, and therapy of the liver. Stem Cell Rev 2(1):51–58Google Scholar
  75. 75.
    Sharma AD, Cantz T, Richter R, Eckert K, Henschler R, Wilkens L, Jochheim-Richter A, Arseniev L, Ott M (2005) Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver. Am J Pathol 167(2):555–564Google Scholar
  76. 76.
    Stadtfeld M, Hochedlinger K (2010) Induced pluripotency: history, mechanisms, and applications. Genes Dev 24(20):2239–2263Google Scholar
  77. 77.
    Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K (2008) Induced pluripotent stem cells generated without viral integration. Science 322(5903):945–949Google Scholar
  78. 78.
    Stockmann HB, Hiemstra CA, Marquet RL, JN IJ (2000) Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 231(4):460–470Google Scholar
  79. 79.
    Storb R, Deeg HJ, Pepe M, Appelbaum F, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R et al (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73(6):1729–1734Google Scholar
  80. 80.
    Storb R, Thomas ED (1985) Graft-versus-host disease in dog and man: the Seattle experience. Immunol Rev 88:215–238Google Scholar
  81. 81.
    Strober W, Fuss I, Mannon P (2007) The fundamental basis of inflammatory bowel disease. J Clin Invest 117(3):514–521Google Scholar
  82. 82.
    Taiani JT, Krawetz RJ, Zur Nieden NI, Elizabeth WuY, Kallos MS, Matyas JR, Rancourt DE (2010) Reduced differentiation efficiency of murine embryonic stem cells in stirred suspension bioreactors. Stem Cells Dev 19(7):989–998Google Scholar
  83. 83.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676Google Scholar
  84. 84.
    Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C (2012) Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307(11):1169–1177Google Scholar
  85. 85.
    Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L, Henegariu O, Krause DS (2000) Liver from bone marrow in humans. Hepatology 32(1):11–16Google Scholar
  86. 86.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147Google Scholar
  87. 87.
    Tiemann U, Sgodda M, Warlich E, Ballmaier M, Schöler HR, Schambach A, Cantz T (2011) Optimal reprogramming factor stoichiometry increases colony numbers and affects molecular characteristics of murine induced pluripotent stem cells. Cytom Part A 79A:426–435Google Scholar
  88. 88.
    Tolar J, Le Blanc K, Keating A, Blazar BR (2010) Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 28(8):1446–1455Google Scholar
  89. 89.
    Trivedi P, Hematti P (2008) Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 36(3):350–359Google Scholar
  90. 90.
    van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML (2008) Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47(5):1634–1643Google Scholar
  91. 91.
    Villa-Diaz LG, Brown SE, Liu Y, Ross AM, Lahann J, Parent JM, Krebsbach PH (2012) Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. Stem Cells 30(6):1174–1181Google Scholar
  92. 92.
    Voelkel C, Galla M, Maetzig T, Warlich E, Kuehle J, Zychlinski D, Bode J, Cantz T, Schambach A, Baum C (2010) Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A 107(17):7805–7810Google Scholar
  93. 93.
    Vosough M, Moslem M, Pournasr B, Baharvand H (2011) Cell-based therapeutics for liver disorders. Br Med Bull 100:157–172Google Scholar
  94. 94.
    Wagner W (2010) Senescence is heterogeneous in mesenchymal stromal cells: kaleidoscopes for cellular aging. Cell Cycle 9(15):2923–2924Google Scholar
  95. 95.
    Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, Ho AD (2008) Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One 3(5):e2213Google Scholar
  96. 96.
    Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M (2003) Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422(6934):897–901Google Scholar
  97. 97.
    Warlich E, Kühle J, Cantz T, Brugman MH, Mätzig T, Galla M, Filipczyk A, Halle S, Klump H, Schöler HR, Baum C, Schroeder T, Schambach A (2011) Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 19(4):782–789Google Scholar
  98. 98.
    Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH (1997) Viable offspring derived from fetal and adult mammalian cells. Nature 385(6619):810–813Google Scholar
  99. 99.
    Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Langholz E, Bodini P, O’Morain C, Katsanos K, Tsianos E, Vermeire S, Van Zeijl G, Limonard C, Hoie O, Vatn M, Moum B, Stockbrugger RW (2006) Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl 243:46–54Google Scholar
  100. 100.
    Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, Bleidissel M, Greber B, Gentile L, Han DW, Rudolph C, Steinemamm D, Schambach A, Ott M, Schöler HR, Cantz T (2011) Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol 9(7):e1001099Google Scholar
  101. 101.
    Yen ML, Hou CH, Peng KY, Tseng PC, Jiang SS, Shun CT, Chen YC, Kuo ML (2011) Efficient derivation & concise gene expression profiling of human embryonic stem cell-derived mesenchymal progenitors (EMPs). Cell Transpl. doi:10.3727/096368910X564067 [Epub ahead of print]
  102. 102.
    Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA (2009) Human induced pluripotent stem cells free of vector and transgene sequences. Science 324(5928):797–801Google Scholar
  103. 103.
    Yu J, Thomson JA (2008) Pluripotent stem cell lines. Genes Dev 22(15):1987–1997Google Scholar
  104. 104.
    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917–1920Google Scholar
  105. 105.
    Zaehres H, Kogler G, Arauzo-Bravo MJ, Bleidissel M, Santourlidis S, Weinhold S, Greber B, Kim JB, Buchheiser A, Liedtke S, Eilken HM, Graffmann N, Zhao X, Meyer J, Reinhardt P, Burr B, Waclawczyk S, Ortmeier C, Uhrberg M, Schöler HR, Cantz T, Wernet P (2010) Induction of pluripotency in human cord blood unrestricted somatic stem cells. Exp Hematol 38(9):809–818Google Scholar
  106. 106.
    Zhang J, Chan YC, Ho JC, Siu CW, Lian Q, Tse HF (2012) Regulation of cell proliferation of human induced pluripotent stem cell-derived mesenchymal stem cells via ether a go–go 1 (hEAG1) potassium channel. Am J Physiol Cell PhysiolGoogle Scholar
  107. 107.
    Zhou W, Freed CR (2009) Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 27(11):2667–2674Google Scholar
  108. 108.
    Zweigerdt R, Olmer R, Singh H, Haverich A, Martin U (2010) Scalable expansion of human pluripotent stem cells in suspension culture. Nat Protoc (in press)Google Scholar

Copyright information

© 2013 2012

Authors and Affiliations

  • Irina Eberle
    • 1
    • 2
  • Mohsen Moslem
    • 1
  • Reinhard Henschler
    • 2
  • Tobias Cantz
    • 1
  1. 1.Junior Research Group Stem Cell Biology, OE 8881, Cluster-of-Excellence REBIRTHHannover Medical SchoolHannoverGermany
  2. 2.DRK-Institute of Transfusion Medicine and Immune HematologyFrankfurtGermany

Personalised recommendations